Pelthos Therapeutics Inc. filed a Form D with the SEC, reporting $57.5M sold, of a $57.5M offering.
What happened
Pelthos Therapeutics Inc. develops and commercializes innovative dermatology therapies, including products for molluscum contagiosum and other skin-health needs. This Form D reports a cash raise of $57.5 million from 7 investors, which signals meaningful capital behind commercialization and makes the company relevant for vendors selling into a growing pharmaceutical operator.
Source
Extracted by Autobound
From the Signal API record- Signal
- Form D offering
What this signalsNew funding often brings new budget and vendor reviews.
- Amount
- $57.5M
- Industry group
- Pharmaceuticals
- Headquarters
- Durham, NC
- Location
- Durham, NORTH CAROLINA
- Filed
- Nov 16, 2026
- Jurisdiction
- Nevada
More form D offering signals at other companies
- Form D offeringGalvanize Therapeutics, Inc.Galvanize Therapeutics, Inc. filed a Form D with the SEC, reporting $136.2M sold, of a $136.2M offering.Form D offering
- Form D offeringRising Tide Dental Holdings, LLCRising Tide Dental Holdings, LLC filed a Form D with the SEC, reporting $61.7M sold, of a $61.7M offering.Form D offering
- Form D offeringAnsa Biotechnologies, Inc.Ansa Biotechnologies, Inc. filed a Form D with the SEC, reporting $54.4M sold, of a $71.9M offering.Form D offering
The full record
From the Signal API recordPeople
- Scott PleshaExecutive Officer, Director · Named in the filing
- John GayExecutive Officer · Named in the filing
- Sai RangaraoExecutive Officer · Named in the filing
- Richard BaxterDirector · Named in the filing
- Peter GreenleafExecutive Officer, Director · Named in the filing
- Ezra FriedbergDirector · Named in the filing
- Todd DavisDirector · Named in the filing
- Richard MalamutDirector · Named in the filing
Numbers
- Amount (USD)
- $57.5M
- Investors
- 7
Details
- CIK
- 0001919246
- Website
- pelthos.com
- SIC code
- 2836
- Form
- D
- Entity type
- Corporation
- Primary topic
- Biotech Fundraise
- Revenue range
- Decline to Disclose
- Business state
- NC
- Accession number
- 0001919246-26-000142
- Resolved entity type
- Operating company
- Has non accredited investors
- No
- Filer
- Pelthos Therapeutics Inc.
- Resolved name
- Pelthos Therapeutics
Topics and mentions
Topics
- Pharmaceuticals
- Commercial-stage
- Dermatology
- Private Placement
- Healthcare Sales
Exemptions
- 06b
Securities
- Equity
- OptionToAcquire
- SecurityToBeAcquired
Extraction
- Confidence
- High
- Relevance
- 80%
- Detected
- Nov 16, 2026
- signal_type
sec-form-d-funding- signal_subtype
newFilingCompany
Use this data
Get every form D offering signal for Pelthos Therapeutics Inc. and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Pelthos Therapeutics Inc. this week?”
Send it to your own tools
The Signal API returns form D offering signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-form-d-funding record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/fd-0001919246-26-000142 returns this record as JSON. POST /v1/companies/enrich returns every signal for pelthos.com.
{
"signal_id": "fd-0001919246-26-000142",
"signal_type": "sec-form-d-funding",
"signal_subtype": "newFilingCompany",
"detected_at": "2026-11-16T00:00:00+00:00",
"company": {
"name": "Pelthos Therapeutics Inc.",
"domain": "pelthos.com"
},
"data": {
"cik": "0001919246",
"phone": "919-908-2400",
"detail": "The filing suggests a company beyond pure research, with commercial products and a focus on expanding therapies for unmet dermatology needs. A $57.5 million cash raise typically supports go-to-market execution, product development, and operating scale, so vendors should watch for spend in commercialization, regulatory/compliance, medical affairs, sales enablement, and enterprise infrastructure.",
"topics": [
"Pharmaceuticals",
"Commercial-stage",
"Dermatology",
"Private Placement",
"Healthcare Sales"
],
"summary": "Pelthos Therapeutics Inc. develops and commercializes innovative dermatology therapies, including products for molluscum contagiosum and other skin-health needs. This Form D reports a cash raise of $57.5 million from 7 investors, which signals meaningful capital behind commercialization and makes the company relevant for vendors selling into a growing pharmaceutical operator.",
"website": "https://pelthos.com",
"location": "Durham, NORTH CAROLINA",
"sic_code": "2836",
"file_date": "2026-11-16",
"form_type": "D",
"relevance": 0.8,
"confidence": "high",
"exemptions": [
"06b"
],
"filing_url": "https://www.sec.gov/Archives/edgar/data/1919246/000191924626000142/",
"source_url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001919246&type=D&dateb=&owner=include&count=40",
"entity_name": "Pelthos Therapeutics Inc.",
"entity_type": "Corporation",
"jurisdiction": "NEVADA",
"primary_topic": "Biotech Fundraise",
"revenue_range": "Decline to Disclose",
"business_state": "NC",
"industry_group": "Pharmaceuticals",
"related_persons": [
{
"name": "Scott Plesha",
"email": "s***@pelthos.com",
"roles": [
"Executive Officer",
"Director"
],
"linkedin_url": "https://www.linkedin.com/in/scott-plesha-63ba50b3"
},
{
"name": "John Gay",
"roles": [
"Executive Officer"
]
},
{
"name": "Sai Rangarao",
"email": "s***@pelthos.com",
"roles": [
"Executive Officer"
],
"linkedin_url": "https://www.linkedin.com/in/sai-rangarao-88635122"
},
{
"name": "Richard Baxter",
"roles": [
"Director"
]
},
{
"name": "Peter Greenleaf",
"roles": [
"Executive Officer",
"Director"
]
},
{
"name": "Ezra Friedberg",
"roles": [
"Director"
]
},
{
"name": "Todd Davis",
"roles": [
"Director"
]
},
{
"name": "Richard Malamut",
"roles": [
"Director"
]
}
],
"total_investors": 7,
"accession_number": "0001919246-26-000142",
"securities_types": [
"Equity",
"OptionToAcquire",
"SecurityToBeAcquired"
],
"business_location": "Durham, NC",
"total_amount_sold": 57500000,
"resolved_entity_name": "Pelthos Therapeutics",
"resolved_entity_type": "operating_company",
"total_offering_amount": 57500000,
"company_domain_confidence": 10,
"has_non_accredited_investors": false
}
}
curl https://signals.autobound.ai/v1/signals/fd-0001919246-26-000142 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"pelthos.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.